Antithrombotic Treatment After Surgical and Transcatheter Heart Valve Repair and Replacement
Copyright © 2021 Verstraete, Herregods, Verbrugghe, Lamberigts, Vanassche, Meyns, Oosterlinck, Rega, Adriaenssens, Van Hoof, Keuleers, Vandenbriele, Sinnaeve, Janssens, Dubois, Meuris and Verhamme..
New antithrombotic drugs have been developed, new valve types have been designed and minimally invasive transcatheter techniques have emerged, making the choice of antithrombotic therapy after surgical or transcatheter heart valve repair and replacement increasingly complex. Moreover, due to a lack of large randomized controlled trials many recommendations for antithrombotic therapy are based on expert opinion, reflected by divergent recommendations in current guidelines. Therefore, decision-making in clinical practice regarding antithrombotic therapy for prosthetic heart valves is difficult, potentially resulting in sub-optimal patient treatment. This article compares the 2017 ESC/EACTS and 2020 ACC/AHA guidelines on the management of valvular heart disease and summarizes the available evidence. Finally, we established a convenient consensus on antithrombotic therapy after valve interventions based on over 800 annual cases of surgical and transcatheter heart valve repair and replacement and a multidisciplinary team discussion between the department of cardiovascular diseases and cardiac surgery of the University Hospitals Leuven, Belgium.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Frontiers in cardiovascular medicine - 8(2021) vom: 16., Seite 702780 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Verstraete, Andreas [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 20.09.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fcvm.2021.702780 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329662902 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329662902 | ||
| 003 | DE-627 | ||
| 005 | 20231225205611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fcvm.2021.702780 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM329662902 | ||
| 035 | |a (NLM)34422930 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Verstraete, Andreas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antithrombotic Treatment After Surgical and Transcatheter Heart Valve Repair and Replacement |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.09.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 Verstraete, Herregods, Verbrugghe, Lamberigts, Vanassche, Meyns, Oosterlinck, Rega, Adriaenssens, Van Hoof, Keuleers, Vandenbriele, Sinnaeve, Janssens, Dubois, Meuris and Verhamme. | ||
| 520 | |a New antithrombotic drugs have been developed, new valve types have been designed and minimally invasive transcatheter techniques have emerged, making the choice of antithrombotic therapy after surgical or transcatheter heart valve repair and replacement increasingly complex. Moreover, due to a lack of large randomized controlled trials many recommendations for antithrombotic therapy are based on expert opinion, reflected by divergent recommendations in current guidelines. Therefore, decision-making in clinical practice regarding antithrombotic therapy for prosthetic heart valves is difficult, potentially resulting in sub-optimal patient treatment. This article compares the 2017 ESC/EACTS and 2020 ACC/AHA guidelines on the management of valvular heart disease and summarizes the available evidence. Finally, we established a convenient consensus on antithrombotic therapy after valve interventions based on over 800 annual cases of surgical and transcatheter heart valve repair and replacement and a multidisciplinary team discussion between the department of cardiovascular diseases and cardiac surgery of the University Hospitals Leuven, Belgium | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a anTithrombotic treatment | |
| 650 | 4 | |a surgical valve repair | |
| 650 | 4 | |a surgical valve replacement | |
| 650 | 4 | |a transcatheter aortic valve implantation | |
| 650 | 4 | |a transcatheter valve repair | |
| 650 | 4 | |a transcatheter valve replacement | |
| 650 | 4 | |a valve intervention | |
| 650 | 4 | |a valvular heart disease | |
| 700 | 1 | |a Herregods, Marie Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Verbrugghe, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Lamberigts, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Vanassche, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Meyns, Bart |e verfasserin |4 aut | |
| 700 | 1 | |a Oosterlinck, Wouter |e verfasserin |4 aut | |
| 700 | 1 | |a Rega, Filip |e verfasserin |4 aut | |
| 700 | 1 | |a Adriaenssens, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Van Hoof, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Keuleers, Siegmund |e verfasserin |4 aut | |
| 700 | 1 | |a Vandenbriele, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Sinnaeve, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Janssens, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Dubois, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Meuris, Bart |e verfasserin |4 aut | |
| 700 | 1 | |a Verhamme, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in cardiovascular medicine |d 2014 |g 8(2021) vom: 16., Seite 702780 |w (DE-627)NLM255534736 |x 2297-055X |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |g day:16 |g pages:702780 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fcvm.2021.702780 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 |b 16 |h 702780 | ||